Sign in
SuspendedNo phase

Submucosal Tumor Removal by Endoscopic Excision Therapy

Key facts

Who runs it
Universitätsklinikum Hamburg-Eppendorf
Where
Germany3 sites in 1 countryChoose a country to see its locations
Trial code
Status
Suspended
People taking part
200 people, planned
Started
10 Mar 2020
Ended
Feb 2025
Type of study
Interventional
Treatments tested
  • removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)
Record updated
19 March 2024
Why it stopped
interim analysis

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Patients with endoscopically diagnosed and endosonographically confirmed submucosal tumors of 0.5 to 2 cm in the stomach without definitive histology / cytology
  • Initial diagnosis less than 2 years ago
  • No contraindication to endoscopic resection
  • Patient's informed consent

Who cannot take part

  • Tumors with proven / suspected malignancy for which oncologically no endoscopic resection should be performed, i.e. for which oncological or surgical therapy is planned
  • Patients with severe general illnesses (limited operability) or malignancies
  • Clotting disorders
  • SMT known > 2 Years
  • Tumor size > 2 cm
  • Pregnancy

Where is this trial?

It has locations in one country. Choose a country to see its locations.

What happens in this trial

What the trial wants to find out

Smaller submucosal tumors (SMT) in the stomach are usually seen as an incidental finding during a gastroscopy, although current diagnostics usually do not clearly indicate what type of tumor it is. In summary, there is no good evidence for dealing with SMT. In this study, an endoscopic full-thickness resection, primarily with the FTRD device, is to be offered to all patients with gastric SMT without a confirmed histology seen in a certain period of time . Patients who do not want to take advantage of this are included in a systematic follow-up program.

Read full original descriptionShow less

The investigators hope to learn about the rate of so-called GIST tumors and other histologies, as well as the rate of change in the follow-up group.

Also, study contents will be accuracy of endosonographic imaging and puncture in comparison with resection histology, technical feasibility and histological completeness of the FTRD- based endoscopic (full-wall) resection option, complications of such a resection (secondary bleeding and dehiscences), and patient preferences with standardized information.

The group in the trial

  • Removal of submucosal gastric tumor preferably by Full Thickness Resection Device (FTRD)Other group

    FTRD (Ovesco company) in tumors up to 10 mm and predominantly intraluminal growth directly by sucking into the cap, at 10-20 mm and/or intramural/extramural growth by prior circumcision and lateral preparation, so that the lesions can be better pulled into the cap. The procedure depends on the endosonographic extent of the findings. The lesions are pulled into the cap with grippers and other instruments and, if necessary, with a snare and then resected with FTRD

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective One-armed Observational Study of Full-thickness Resection of Small Hypoechoic Submucosal Gastric Tumors (≤2 cm)
Record updated
19 March 2024